Posted inAllergy & Immunology Dermatology news
Beyond Antihistamines: Dupilumab Emerges as a Potent Strategy for Refractory Chronic Spontaneous Urticaria
The Phase 3 LIBERTY-CSU CUPID trials demonstrate that dupilumab significantly reduces itch and hives in patients with chronic spontaneous urticaria uncontrolled by antihistamines, providing a crucial new therapeutic option for those who are anti-IgE naive.